Thrombopoietin Receptor Agonists [MoA]

Known as: Thrombopoietin Receptor Agonists 
 
National Institutes of Health

Related topics

Related topics

2 relations
eltrombopagromiplostim

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Use of romiplostim for refractory primary immune thrombocytopenia during pregnancy
Background: Data on the safety and efficacy of thrombopoietin receptor agonists (TRAs) in pregnancy are very limited, although… (More)
Is this relevant?
2016
2016
Outpatient Management of Patients with Immune Thrombocytopenia (ITP) by Hematologists 1995-2014.
BACKGROUND The aim of this study was to evaluate the treatment reality for outpatients with immune thrombocytopenia (ITP) managed… (More)
  • table 1
  • figure 1
Is this relevant?
Review
2016
Review
2016
Advances in Diagnosis and Treatments for Immune Thrombocytopenia
Immune thrombocytopenia (ITP) is an acquired hemorrhagic condition characterized by the accelerated clearance of platelets caused… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2016
2016
Thrombopoietin Receptor Agonists Are Often Ineffective in Immune Thrombocytopenia and/or Cause Adverse Reactions: Results from One Hand.
BACKGROUND Eltrombopag and romiplostim are thrombopoietin receptor agonists (TPOs) that have been increasingly used for the… (More)
  • table 3
  • table 1
  • table 2
  • figure 1
  • table 4
Is this relevant?
2016
2016
Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines
Very few data exist on the management of adult patients diagnosed with primary immune thrombocytopenia (ITP). The objectives of… (More)
  • table 1
  • table 3
  • table 4
  • table 5
Is this relevant?
2013
2013
Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.
BACKGROUND Thrombopoietin receptor agonists (TRAs) are effective treatments for immune thrombocytopenia (ITP). However… (More)
Is this relevant?
2013
2013
Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
BACKGROUND AND OBJECTIVES Thrombopoietin receptor agonists (TPOra) are the only treatments for immune thrombocytopenia (ITP) for… (More)
  • figure 1
  • table 2
  • table 3
  • figure 2
  • figure 3
Is this relevant?
2013
2013
Long-term follow-up of concomitant treatment with romiplostim and warfarin in a patient with immune thrombocytopenia and severe cardiac comorbidities.
Thrombopoietin receptor agonists (TRAs) offer new opportunities for the treatment of chronic immune thrombocytopenia (ITP… (More)
  • figure 1
Is this relevant?
2013
2013
Bone Marrow Fibrosis In Immune Thrombocytopenia (ITP) Patients Treated With Thrombopoietin Receptor Agonists (TRA) – a Single Center Long-Term Follow-Up
 
Is this relevant?
2012
2012
Platelet Kinetics in Idiopathic Thrombocytopenic Purpura Patients Treated with Thrombopoietin Receptor Agonists.
AIM: Thrombopoietin receptor agonists (Tpo RA) increase platelet counts in the majority of chronic autoimmune thrombocytopenia… (More)
  • table 1
  • table 2
  • figure 2
Is this relevant?